Cargando…
Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women
Concurrent cohorts of 644,932 women aged 50–74 screened annually due to family history, dense breasts or biennially in the Ontario Breast Screening Program (OBSP) from 2011–2014 were linked to provincial administrative datasets to determine health system resource utilization and costs. Age-adjusted...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529052/ https://www.ncbi.nlm.nih.gov/pubmed/37754535 http://dx.doi.org/10.3390/curroncol30090620 |
_version_ | 1785111341706510336 |
---|---|
author | Mittmann, Nicole Blackmore, Kristina M. Seung, Soo Jin Diong, Christina Done, Susan J. Chiarelli, Anna M. |
author_facet | Mittmann, Nicole Blackmore, Kristina M. Seung, Soo Jin Diong, Christina Done, Susan J. Chiarelli, Anna M. |
author_sort | Mittmann, Nicole |
collection | PubMed |
description | Concurrent cohorts of 644,932 women aged 50–74 screened annually due to family history, dense breasts or biennially in the Ontario Breast Screening Program (OBSP) from 2011–2014 were linked to provincial administrative datasets to determine health system resource utilization and costs. Age-adjusted mean and median total healthcare costs (2018 CAD) and incremental cost differences were calculated by screening outcome and compared by recommendation using regression models. Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast cancer diagnosis (n = 6011). Mean overall healthcare costs by age were highest for those 60–74, particularly with annual screening for family/personal history (CAD 5425; 95% CI: 5308 to 5557) compared to biennial. Although the mean incremental cost difference was higher (23.4%) by CAD 10,235 (95% CI: 6141 to 14,329) per breast cancer for women screened annually for density ≥ 75% compared to biennially, the cost difference was 12.0% lower (−CAD 461; 95% CI: −777 to −114) per false positive result. In contrast, for women screened annually for family/personal history, the mean cost difference per false positive was 19.7% higher than for biennially (CAD 758; 95% CI: 404 to 1118); however, the cost difference per breast cancer was only slightly higher (2.5%) by CAD 1093 (95% CI: −1337 to CAD 3760). Understanding that associated costs of annual compared to biennial screening may balance out by age and outcome can assist decision-making regarding the use of limited healthcare resources. |
format | Online Article Text |
id | pubmed-10529052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105290522023-09-28 Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women Mittmann, Nicole Blackmore, Kristina M. Seung, Soo Jin Diong, Christina Done, Susan J. Chiarelli, Anna M. Curr Oncol Article Concurrent cohorts of 644,932 women aged 50–74 screened annually due to family history, dense breasts or biennially in the Ontario Breast Screening Program (OBSP) from 2011–2014 were linked to provincial administrative datasets to determine health system resource utilization and costs. Age-adjusted mean and median total healthcare costs (2018 CAD) and incremental cost differences were calculated by screening outcome and compared by recommendation using regression models. Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast cancer diagnosis (n = 6011). Mean overall healthcare costs by age were highest for those 60–74, particularly with annual screening for family/personal history (CAD 5425; 95% CI: 5308 to 5557) compared to biennial. Although the mean incremental cost difference was higher (23.4%) by CAD 10,235 (95% CI: 6141 to 14,329) per breast cancer for women screened annually for density ≥ 75% compared to biennially, the cost difference was 12.0% lower (−CAD 461; 95% CI: −777 to −114) per false positive result. In contrast, for women screened annually for family/personal history, the mean cost difference per false positive was 19.7% higher than for biennially (CAD 758; 95% CI: 404 to 1118); however, the cost difference per breast cancer was only slightly higher (2.5%) by CAD 1093 (95% CI: −1337 to CAD 3760). Understanding that associated costs of annual compared to biennial screening may balance out by age and outcome can assist decision-making regarding the use of limited healthcare resources. MDPI 2023-09-18 /pmc/articles/PMC10529052/ /pubmed/37754535 http://dx.doi.org/10.3390/curroncol30090620 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mittmann, Nicole Blackmore, Kristina M. Seung, Soo Jin Diong, Christina Done, Susan J. Chiarelli, Anna M. Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title | Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title_full | Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title_fullStr | Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title_full_unstemmed | Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title_short | Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women |
title_sort | healthcare and cancer treatment costs of breast screening outcomes among higher than average risk women |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529052/ https://www.ncbi.nlm.nih.gov/pubmed/37754535 http://dx.doi.org/10.3390/curroncol30090620 |
work_keys_str_mv | AT mittmannnicole healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen AT blackmorekristinam healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen AT seungsoojin healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen AT diongchristina healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen AT donesusanj healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen AT chiarelliannam healthcareandcancertreatmentcostsofbreastscreeningoutcomesamonghigherthanaverageriskwomen |